EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

RB1 inactivation in cutaneous carcinomas

Tiffany Liv iD, Antoine Touzé iD, David Schrama iD, Serge Guyétant iD, Mahtab Samimi iD, Michael T Tetzlaff iD, Benjamin A Wood iD, Paul W Harms iD, Thibault Kervarrec iD

Histopathology · 2026-03 · 88 (4) · 769-789

DOI: 10.1111/his.70056 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 15.12.2025. Verfasst von Tiffany Liv und 8 weiteren Autor:innen. Beteiligte Einrichtung: Équipe Biologie des Infections à Polyomavirus, UMR INRAE ISP 1282, Université de Tours, Tours, France. Hauptthemen laut MEDLINE: Skin Neoplasms, Retinoblastoma Binding Proteins, Ubiquitin-Protein Ligases, Retinoblastoma Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RB1 was the first identified tumour suppressor gene, named for its crucial role in opposing retinoblastoma oncogenesis. The RB1 gene encodes the retinoblastoma protein pRB, which is a well‐known negative regulator of the cell cycle. However, pRB also contributes to cell differentiation by restricting reprogramming and stem cell properties. Accordingly, RB1 inactivation in tumours can induce phenotypic modifications, contributing to tumour progression. Indeed, RB1 pathogenic alterations, either point mutations or deletions, leading to pRB loss of function are observed in 5% of all human cancers. Mutations are much more prevalent in some histologic subgroups, including retinoblastoma, spindle cell lipoma, neuroendocrine prostate cancer and small cell lung carcinoma. In such entities, molecular investigation of tumour samples and mechanistic studies strongly suggest that early RB1 inactivation contributes not only to dysregulation of cell cycle control, but also to the tumour cell phenotype. Among skin carcinomas, RB1 inactivation is the hallmark of primary cutaneous neuroendocrine carcinoma commonly known as Merkel cell carcinoma (MCC), but it has also been described in other tumours including a subset of squamous cell carcinomas, sebaceous carcinomas and the recently described Wnt/beta‐catenin‐activated non‐pilomatrical carcinomas. In this context, we provide a brief overview of the contribution of RB1 inactivation to oncogenesis and tumour cell phenotypes in general and summarise current knowledge regarding RB1‐deficient cutaneous carcinomas, highlighting the potential uses of RB1 pathway characterisation for diagnosis, prognosis and therapeutic purposes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesRetinoblastoma ProteinHumansCarcinoma, NeuroendocrineCarcinoma, Merkel Cell

Stichwörter der Autor:innen

Merkel cell carcinomaRB1Wnt/beta‐catenin non pilomatrical carcinomasebaceous carcinomasquamous cell carcinoma

Substanzen

RB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesRetinoblastoma Protein

Autor:innen und Institutionen

  • Équipe Biologie des Infections à Polyomavirus, UMR INRAE ISP 1282, Université de Tours, Tours, France.
  • Departments of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Département de Pathologie, Université de Tours, Tours, France.
  • Département de Dermatologie, Université de Tours, Tours, France.
  • CARADERM Network, France.
  • Department of pathology, University of California, San Francisco, California, USA.

ORCID-Profile: Tiffany Liv, Antoine Touzé, David Schrama, Serge Guyétant, Mahtab Samimi, Michael T Tetzlaff, Benjamin A Wood, Paul W Harms, Thibault Kervarrec

Zitieren

APA

Liv, T., Touzé, A., Schrama, D., Guyétant, S., Samimi, M., Tetzlaff, M. T., Wood, B. A., Harms, P. W., & Kervarrec, T. (2026). RB1 inactivation in cutaneous carcinomas. Histopathology, 88(4), 769-789. https://doi.org/10.1111/his.70056

Vancouver

Liv T, Touzé A, Schrama D, Guyétant S, Samimi M, Tetzlaff MT, et al. RB1 inactivation in cutaneous carcinomas. Histopathology. 2026;88(4):769-789. doi:10.1111/his.70056

BibTeX
@article{Liv2026,
  author = {Liv, Tiffany and Touzé, Antoine and Schrama, David and Guyétant, Serge and Samimi, Mahtab and Tetzlaff, Michael T and Wood, Benjamin A and Harms, Paul W and Kervarrec, Thibault},
  title = {RB1 inactivation in cutaneous carcinomas},
  journal = {Histopathology},
  year = {2026},
  volume = {88},
  number = {4},
  pages = {769--789},
  doi = {10.1111/his.70056}
}
Kostenlos starten →